Literature DB >> 10559919

Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies.

R M Grady1, R W Grange, K S Lau, M M Maimone, M C Nichol, J T Stull, J R Sanes.   

Abstract

A dystrophin-containing glycoprotein complex (DGC) links the basal lamina surrounding each muscle fibre to the fibre's cytoskeleton, providing both structural support and a scaffold for signalling molecules. Mutations in genes encoding several DGC components disrupt the complex and lead to muscular dystrophy. Here we show that mice deficient in alpha-dystrobrevin, a cytoplasmic protein of the DGC, exhibit skeletal and cardiac myopathies. Analysis of double and triple mutants indicates that alpha-dystrobrevin acts largely through the DGC. Structural components of the DGC are retained in the absence of alpha-dystrobrevin, but a DGC-associated signalling protein, nitric oxide synthase, is displaced from the membrane and nitric-oxide-mediated signalling is impaired. These results indicate that both signalling and structural functions of the DGC are required for muscle stability, and implicate alpha-dystrobrevin in the former.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559919     DOI: 10.1038/12034

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  100 in total

Review 1.  Clustering of nicotinic acetylcholine receptors: from the neuromuscular junction to interneuronal synapses.

Authors:  Kyung-Hye Huh; Christian Fuhrer
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  The interaction with HMG20a/b proteins suggests a potential role for beta-dystrobrevin in neuronal differentiation.

Authors:  Benedetta Artegiani; Catherine Labbaye; Antonella Sferra; Maria Teresa Quaranta; Paola Torreri; Gianfranco Macchia; Marina Ceccarini; Tamara C Petrucci; Pompeo Macioce
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

3.  α-Dystrobrevin distribution and association with other proteins in human promyelocytic NB4 cells treated for granulocytic differentiation.

Authors:  V V Borutinskaite; K-E Magnusson; R Navakauskiene
Journal:  Mol Biol Rep       Date:  2010-01-29       Impact factor: 2.316

4.  Dystrophin-associated protein scaffolding in brain requires alpha-dystrobrevin.

Authors:  April D Bragg; Sonal S Das; Stanley C Froehner
Journal:  Neuroreport       Date:  2010-07-14       Impact factor: 1.837

5.  Α-Dystrobrevin-1 recruits Grb2 and α-catulin to organize neurotransmitter receptors at the neuromuscular junction.

Authors:  Jacinthe Gingras; Marta Gawor; Krzysztof M Bernadzki; R Mark Grady; Peter Hallock; David J Glass; Joshua R Sanes; Tomasz J Proszynski
Journal:  J Cell Sci       Date:  2016-01-14       Impact factor: 5.285

6.  Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress.

Authors:  Jana Strakova; Jon D Dean; Katharine M Sharpe; Tatyana A Meyers; Guy L Odom; DeWayne Townsend
Journal:  J Mol Cell Cardiol       Date:  2014-08-24       Impact factor: 5.000

7.  The knockdown of αkap alters the postsynaptic apparatus of neuromuscular junctions in living mice.

Authors:  Isabel Martinez-Pena Y Valenzuela; Mohamed Aittaleb; Po-Ju Chen; Mohammed Akaaboune
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

8.  Association of alpha-dystrobrevin with reorganizing tight junctions.

Authors:  A Sjö; K E Magnusson; K H Peterson
Journal:  J Membr Biol       Date:  2005-01       Impact factor: 1.843

Review 9.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

10.  Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy.

Authors:  Laurin M Hanft; Daniel J Bogan; Ulrike Mayer; Stephen J Kaufman; Joe N Kornegay; James M Ervasti
Journal:  Neuromuscul Disord       Date:  2007-05-01       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.